Drugs / 89Zr-ss-pertuzumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04692831 | Nov 2020 → Nov 2027 expected | HER2 positive breast carcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-ss-pertuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04692831 ↗ |
| Known as | 89Zr-site-specific (ss)-pertuzumab | “Here, we describe a first-in-human PET study on patients with HER2-positive breast cancer evaluating the safety, biodistribution, and dosimetry of 89Zr-site-specific...” PMID 38272704 ↗ Mar 2024 |
| Modality | Diagnostic / imaging agent | “89Zr-ss-pertuzumab PET/CT was used to assess HER2 status and heterogeneity to guide biopsy and decide the next line of treatment at progression.” PMID 38272704 ↗ Mar 2024 |
| Route | Intravenous | “Patients were administered 74 MBq of 89Zr-ss-pertuzumab in 20 mg of total antibody intravenously and underwent PET/CT at 1 d, 3-4 d, and 5-8 d after injection.” PMID 38272704 ↗ Mar 2024 |